Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Favipiravir Against Severe Ebola Virus Disease

NCT02662855 is registered in ClinicalTrials.gov with Beijing Institute of Pharmacology and Toxicology as lead sponsor.

NCT NCT02662855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02662855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Favipiravir Against Severe Ebola Virus Disease
Lead sponsor
Beijing Institute of Pharmacology and Toxicology
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
May 31, 2015
Enrollment
77 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ebola virus disease